University of Groningen

Use of real-world evidence in pharmacoeconomic analysis

Huang, Yunyu

DOI:
[10.33612/diss.95669767](https://doi.org/10.33612/diss.95669767)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Huang, Y. (2019). *Use of real-world evidence in pharmacoeconomic analysis: illustrations in The Netherlands and China*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen. <https://doi.org/10.33612/diss.95669767>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Use of Real-World Evidence in Pharmacoeconomic Analysis

Illustrations for The Netherlands and China

Yunyu Huang

Yunyu Huang

Use of Real-World Evidence in Pharmacoeconomic Analysis: Illustrations for The Netherlands and China

PhD dissertation, University of Groningen, University Medical Center Groningen, the Netherlands

The work presented in this thesis results from a joint Doctorate between the University of Groningen, University Medical Center Groningen, and Fudan University (Shanghai, China).

Financial support for the publication of this thesis was partially provided by the University of Groningen, University Medical Center Groningen, and Research Institute SHARE (Science in Healthy Ageing & healthcaRE).

ISBN: 978-94-034-1870-4 (printed version)
978-94-034-1869-8 (digital version)

Cover design and layout: Eduard Boxem | www.persoonlijkproefschrift.nl

Printing: Ridderprint BV | www.ridderprint.nl

© 2019, Yunyu Huang, Groningen, the Netherlands

All rights reserved. No parts of this thesis may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system, without permission of the author.

**university of
 groningen**

Use of Real-World Evidence in Pharmacoeconomic Analysis

Illustrations for The Netherlands and China

PhD thesis

to obtain the degree of PhD at the
University of Groningen
on the authority of the
Rector Magnificus Prof. C. Wijmenga
and in accordance with
the decision by the College of Deans.

This thesis will be defended in public on

Monday 16 September 2019 at 11:00 hours

by

Yunyu Huang

born on 29 August 1985
in Shanghai, China

Supervisors

Prof. F.M. Haaijer-Ruskamp

Prof. M.J. Postma

Co-supervisor

Dr. P. Vemer

Assessment committee

Prof. K. Taxis

Prof. S.M.A.A. Evers

Prof. H.V. Hogerzeil

Paranymphs

Dr. J.F.M. van Boven

Dr. H. Wang

TABLE OF CONTENTS

Chapter 1	Introduction	9
Chapter 2	Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review	21
Chapter 3	Using primary care electronic health record data for comparative effectiveness research: experience of data quality assessment and preprocessing in The Netherlands	61
Chapter 4	Comparing the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on renal function decline in diabetes	81
Chapter 5	Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data	105
Chapter 6	Cost-effectiveness and budget impact analysis of improvement of medication utilization in patients with type 2 diabetes and nephropathy from a healthcare payer perspective in China	127
Chapter 7	General discussion and future perspectives	155
Summary		168
Appendices		
	Nederlandse samenvatting	172
	Acknowledgments	176
	About the author	178